157 related articles for article (PubMed ID: 38091810)
21. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.
Liu M; Tseng TC; Jun DW; Yeh ML; Trinh H; Wong GLH; Chen CH; Peng CY; Kim SE; Oh H; Kwak MS; Cheung M; Toyoda H; Hsu YC; Jeong JY; Yoon EL; Ungtrakul T; Zhang J; Xie Q; Ahn SB; Enomoto M; Shim JJ; Cunningham C; Jeong SW; Cho YK; Ogawa E; Huang R; Lee DH; Takahashi H; Tsai PC; Huang CF; Dai CY; Tseng CH; Yasuda S; Kozuka R; Li J; Wong C; Wong CC; Zhao C; Hoang J; Eguchi Y; Wu C; Tanaka Y; Gane E; Tanwandee T; Cheung R; Yuen MF; Lee HS; Yu ML; Kao JH; Yang HI; Nguyen MH
Hepatol Int; 2021 Feb; 15(1):71-81. PubMed ID: 33394321
[TBL] [Abstract][Full Text] [Related]
22. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
Chayanupatkul M; Omino R; Mittal S; Kramer JR; Richardson P; Thrift AP; El-Serag HB; Kanwal F
J Hepatol; 2017 Feb; 66(2):355-362. PubMed ID: 27693539
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
24. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
25. High Prevalence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection in Thailand.
Wanich N; Vilaichone RK; Chotivitayatarakorn P; Siramolpiwat S
Asian Pac J Cancer Prev; 2016; 17(6):2857-60. PubMed ID: 27356702
[TBL] [Abstract][Full Text] [Related]
26. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.
Lin D; Yang HI; Nguyen N; Hoang J; Kim Y; Vu V; Le A; Chaung K; Nguyen V; Trinh H; Li J; Zhang J; Hsing A; Chen CJ; Nguyen MH
Aliment Pharmacol Ther; 2016 Oct; 44(8):846-55. PubMed ID: 27549411
[TBL] [Abstract][Full Text] [Related]
27. Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus.
Yip TC; Wong GL; Chan HL; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Kong AP; Wong VW
J Gastroenterol Hepatol; 2020 Dec; 35(12):2210-2219. PubMed ID: 32343449
[TBL] [Abstract][Full Text] [Related]
28. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study.
Ahn J; Lim JK; Lee HM; Lok AS; Nguyen M; Pan CQ; Mannalithara A; Te H; Reddy KR; Trinh H; Chu D; Tran T; Lau D; Leduc TS; Min A; Trong Le L; Bae H; Van Tran S; Do S; Hann HW; Wong C; Han S; Pillai A; Park JS; Tong M; Scaglione S; Woog J; Kim WR
Am J Gastroenterol; 2016 Sep; 111(9):1297-304. PubMed ID: 27325221
[TBL] [Abstract][Full Text] [Related]
29. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
Yu JH; Suh YJ; Jin YJ; Heo NY; Jang JW; You CR; An HY; Lee JW
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):865-872. PubMed ID: 30694912
[TBL] [Abstract][Full Text] [Related]
30. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
31. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.
Su TH; Peng CY; Tseng TC; Yang HC; Liu CJ; Liu CH; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2020 Feb; 221(4):589-597. PubMed ID: 31574141
[TBL] [Abstract][Full Text] [Related]
32. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
33. Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study.
Yun B; Oh J; Ahn SH; Yoon JH; Kim BK
Am J Gastroenterol; 2023 Jun; 118(6):1001-1009. PubMed ID: 36288330
[TBL] [Abstract][Full Text] [Related]
34. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.
Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M;
Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395
[TBL] [Abstract][Full Text] [Related]
35. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
Jang H; Yoon JS; Park SY; Lee HA; Jang MJ; Kim SU; Sinn DH; Seo YS; Kim HY; Kim SE; Jun DW; Yoon EL; Sohn JH; Ahn SB; Shim JJ; Jeong SW; Cho YK; Kim HS; Nam JY; Lee YB; Kim YJ; Yoon JH; Zoulim F; Lampertico P; Dalekos GN; Idilman R; Sypsa V; Berg T; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Janssen H; Papatheodoridis GV; Lee JH
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1343-1353.e16. PubMed ID: 34500103
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
Dave S; Park S; Murad MH; Barnard A; Prokop L; Adams LA; Singh S; Loomba R
Hepatology; 2021 Jan; 73(1):68-78. PubMed ID: 32277491
[TBL] [Abstract][Full Text] [Related]
37. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
Huang X; Wang H; Zhang W; Gu E
Eur J Gastroenterol Hepatol; 2022 May; 34(5):546-552. PubMed ID: 35170528
[TBL] [Abstract][Full Text] [Related]
38. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
[TBL] [Abstract][Full Text] [Related]
39. Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A population-based cohort study.
Shyu YC; Huang TS; Chien CH; Yeh CT; Lin CL; Chien RN
J Viral Hepat; 2019 Jun; 26(6):718-726. PubMed ID: 30739359
[TBL] [Abstract][Full Text] [Related]
40. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.
Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH
Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
